INDEX

A

Absorption, 216
Accreditation Commission for Health Care, standards, 17
Accrediting Agencies for Healthcare Organizations, standards, 9
Accuracy, 366–367
ACS, 396–397
Adsorption, 216
Adverse drug events, 1–6
  clinical, 3–4
  immediate use compounding and, 37
Air monitoring, 276
Air particulate counters, 123
Air sampling, 433
  action levels, documentation, data evaluation for, 434
  devices for, 433
  nonviable, 429–430
  viable, 430
Airflow
  loading, compounding areas, 398
  unidirectional, 133–134
Aldesleukin, 216
Allergen extracts, 338
  personnel cleansing, garbing for, 156
Allergen immunotherapy, 44, 46
Alternate site care settings, 220
Aluminum, 61
  contamination, FDA mandate and, 97, 100
  content of infant vaccines and, 92–94
  load calculation for, 101
  toxicity of, 90–91
Ambient light protection, 100–101
Ambulatory care pharmacies, 10
Ambulatory infusion center, 17
Ambulatory infusion devices, reservoirs, multiday, 222
American Academy of Allergy, Asthma, and Immunology, 46
American Academy of Otolaryngic Allergy, 46
American Academy of Pediatrics
  decision support and, 105
  excipients and, 87
American Nurses Association, medication errors, 44
American Osteopathic Association, 480
  Healthcare Facilities Accreditation Program, 9
American Pharmacists Association
  nuclear pharmacy and, 209
  on ophthalmic formulas, 63–64
  on parenteral formulas, 62
  sterile compounding and, 36
American Society for Parenteral and Enteral Nutrition (ASPEN)
  guidelines of, 27
  on parenteral nutrition additives, 95
  on parenteral nutrition compounding, 72–74
  on parenteral nutrition order review, 71–72
  on parenteral nutrition prescribing, 70–71
  on parenteral nutrition quality assurance, 75–76
  on parenteral nutrition safe practices, toolkit, 69–70
  survey by, 68–69
American Society for Testing and Materials (ASTM), 27
  glove permeability standards of, 184–185
Amino acids, 96
Amphotericin, 56
Ampules
  aseptic technique for, 167–168
  automated compounding systems and, 382
Ante area/room, 116, 340, 351–353
  cleaning, disinfecting program for, 420–421, 469–472
  cleanliness zone and, 428–429
  disinfectants for, 417, 418–419
  janitorial procedures for, 419
Antimicrobial cleansing products, 156–157
Antimicrobial effectiveness test, 268
Antimicrobial preservatives, 56–57, 268
Antineoplastics, 174–175
Antioxidants, 57
Appearance, finished preparation, 261
Aqueous isotonic vehicles, 55
Architectural schematic plan, 355–356
Arsenic trioxide, 194
Aseptic manipulation competency evaluation, 448
Aseptic processing, biological issues, 272
Aseptic technique, 2, 3, 161–170
  for ampules, 167–168
  biological issues in, 267
  for CSPs, 168–169
  equipment, environment and, 162–163
  hand hygiene and, 164
  for hazardous drugs, 192
  for needles, 165–166
  personnel cleansing, gowning and, 163–164
  for radiopharmaceuticals, 207–210
  requirements for, 162
  for syringes, 164–165
  for vials, 166–167
ASHP
  Accreditation of Pharmacy Residency Programs, 27
  Accreditation of Pharmacy Technician Training Programs, 27
  continuing education resources of, 320
  CSP guidelines by, 489–516
  guidelines by, 27
  hazardous drugs and, 172
  hazardous drugs guidelines by, 517–543
  hospital pharmacy practice surveys by, 67–69
  National Surveys of Pharmacy Practice, 2
  ophthalmic formulas and, 63–64
  outsourcing pharmacy and, 481–482
  Pharmacy Informatics and Technology, 386–387
  on pharmacy technician accreditation, 325–326
  practice standards of, 26
  resources on sterile compounding, 27
  safety initiative of, 106
  sterile compounding guidelines of, 545–546
  on syringes and CSP storage, 478
  Technical Assistance Bulletin on *Handling Cytotoxic and Hazardous Drugs*, 176, 177, 178
  Technical Assistance Bulletin on *Quality Assurance for Pharmacy-Prepared Sterile Products*, 2–3
Association for Professionals in Infection Control and Epidemiology, 40
Automated compounding systems/devices (ACS), 364, 370–371, 374–375
  cleaning, disinfecting, maintenance of, 399
  container closure and, 382
  documentation for, 246
  downtime and, 400–401, 402
  environmental monitoring of, 397–398
  errors with, 69
  hardware failure and, 401
  hardware-software performance of, 398
  infrastructure failure and, 401–402
  large, 376–381
  mixing profiles for, 382
  monitoring performance of, 396–397
  parenteral nutrition compounding workflow process for, 74–75
  pediatric compounding and, 103
  serial dilution and, 382
  small, 376
  software, network failure and, 401
  sterility assurance validation of, 395–396
  surface sampling, assessment of, 398
  throughput validation of, 395
  workflow software for, 381–383
Automated dispensing cabinets (ADCs), 41
Automation
  business case for, 389
  capital expenditure value considerations for, 390
  data collection for, 394–396
  evolution of, 364–365
  go-live, ramp up schedule for, 392–393
  implementation of, 391
  interface design, parallel testing of, 391
  project planning for, 387–388
  project stakeholder engagement for, 388–389
  reasons for, 365–372
  solutions assessment of, 386–387
  stakeholder communication and, 392
  support, issue resolution for, 392
  system build, administration of, 393–395
  system installation, commissioning, 391–392
  training, practice for, 392

B

Backup power, 125
Bacterial endotoxin testing, 262–263
Bacteriostatic sodium chloride injection, 55
Bacteriostatic water, 55
Barcode(s), 240
  for ingredient, 260
Barcoded medication administration (BCMA), 240
Basics of Aseptic Compounding Technique Video Training Program, The, 162, 328
Batch compounding, 303–312
  component quality checks for307–308
  control record for, 311–312
  directions for, 308–309
  documentation of, 310
  equipment, supplies specifications for, 309
  final preparation testing, quarantine of, 309–310
  in-process testing for, 309
  labeling for, 231–232
  master formula for, 307
  master formula sheet for, 304–307
  master worksheets for, 52
  procedure checks for, 308
  record retention for, 310
  sample label for, 309
  schedules for, 406, 407
BCG (bacillus Calmette-Guérin), 114–115
Becton-Dickinson syringes, CSP storage and, 476–478
Benches, 122–123
Benjamin, Bona, 478
Benzyl alcohol, 41, 56, 87–89
Beyond use date(ing), 213–226
  commercial IV solutions after protective overwrap removal and, 299
  determination of, 223–224
  for immediate-use products, 36
  point-of-care activated devices and, 299
  policies and procedures for, 461
Bing, Caryn Dellamorte, 213–226, 295–301

Bioburden, 269, 270
  prefiltration control of, 272
Biohazard
  symbol for, 178
  waste bag for, 118
Biological agents
  cleaning, decontamination and, 117–118
  compounding of, 113–120
  disposal of, 118
  preparation of, 118
  receiving, 116–117
  safe handling of, 116–118
  spills and, 118–119
  storage of, 117
  transportation of, 118–119
  types of, 113–115
Biological indicators, 269, 270
Biological issues, 267–281
  air monitoring for, 276
  antimicrobial effectiveness test for, 268
  antimicrobial preservatives and, 268
  aseptic processing and, 272
  aseptic technique and, 267
  bioburden of, 269
  cleaning, disinfection and, 278–280
  culture media and, 268, 273–274
  depyrogenation and, 274–275
  environmental, personnel sampling, testing for, 275–276
  filter integrity testing for, 272
  hand hygiene and, 276–278
  media fill test and, 273
  microbial risk considerations in, 267–268
  microbiology test stability and, 268–269
  prefiltration bioburden control of, 272
  pyrogens and, 274–275
  sterility and, 269–270
  sterility testing for, 272–273
  sterilization and, 269–270
  sterilization filtration and, 270–271
  sterilization filtration validation and, 271–272
  sterilization of containers and, 274
  sterilization validation and, 270
  surface monitoring for, 275–276
  training, competency and, 280
Biological safety cabinets (BSCs), 118, 138–146
  air barrier for, 139
  air movement within, 140
  biological safety levels and, 115–118
  Class I, 139
  Class II, 115, 139–140, 191
  Class II, Type A1, 139, 140, 141, 142
  Class II, Type A2, 139, 141, 143
  Class II, Type B1, 139, 141–142, 144
  Class II, Type B2, 139, 141, 142–143, 145
  Class III, 115, 139, 144
  equipment and, 115
  hazardous drug compounding and, 144–146
  training and, 115
Biological therapy, 113
Biosafety in Microbiological and Biomedical Laboratories, 116
Boyce, Craig A., 363–407
BSL-1 facility, 116, 117
BSL-2 agents, 118
BSL-2 facility, 116, 117
Bubble diagram, 358
Bubble point tester, 126
Buchanan, E. Clyde, 7–33, 333–362, 473–485
Buffer area/room, 116, 340, 351–353
  cleaning, disinfecting of, 420–421, 469–472
  cleanliness zone and, 429
  disinfectants for, 417, 418–419
  handling products in, 287–288
  ISO Class 7 environment and, 342, 343
  janitorial procedures for, 419
Buffering agents, 57
  for ophthalmic formulations, 62

C

Calcitriol, 216
Calcium salts, 61
Calcium solubility factors, 95–96
Canada, Todd W., 67–79
Capps, Richard C., 133–151
Caregiver training, 462
Carmustine, 185
Carts, 122, 287
Casework, 122
Center for Biologics Evaluation and Research (CBER), 113
Center for Drug Evaluation and Research (CDER), 113
Center for Improvement in Healthcare Quality (CIHQ), 9, 480
  standards of, 12
Centers for Disease Control and Prevention (CDC), 26
  biosafety in facility design and, 116
  hazardous drugs and, 172
  "one and only campaign" of, 42
  pediatric skin cleaning and, 90
Centers for Medicare & Medicaid Services (CMS)
  accreditation and, 479–480
  Conditions of Participation, 9
  immediate-use medication and, 35–36
  medication compounding and, 35
  multiuse vials and, 41–42
  standards and, 9–10
Certificate of analysis, 245, 259
Certification records, 247
Chairs, 122–123
Chelating agents, 57
Chemical degradation, 217–218
Chemical incompatibility, 214
Chemotherapy
  gloves for, 184–186, 190
  waste and, 292
Chlorhexidine gluconate, 90–91, 157
Chloroxylenol, 157
Chromium, 195
Cleaning, 409–423
  of ACS, 399
  assessment form for, 411
  biological agents and, 117–118
  biological issues of, 278–280
  of buffer area, ante area, 469–472
  competency evaluation of, 448–449
  compounding areas and frequency of, 413
  of facility, 359–360
  program setup for, 420–421
  supplies for, 126
Cleanliness zone
  ante-area and, 428–429
  buffer area and, 429
  containment segregated compounding area and, 429
  general pharmacy area and, 429
  segregated compounding area and, 429
Cleanroom
  facilities for, 339
  furniture for, 122–123
  garb for, 127–128
  standards for, 30
Closed isolators, 147
Closed system drug-transfer device (CSTD), 116, 128, 182–183, 191
Closures, 59
Cold, 220
Commissioning for occupancy, 359
Compatibility, filter, 251
Competence Assessment Tools for Health-System Pharmacies, 329
Competency, biological issues, 280
Component(s), 55–59
  quality checks, batch compounding and, 307–308
  standards for, 258–259
Compounding
  defined, 8
  of hazardous drugs, 337–338
  personnel responsibility for, 19
  robots for, 364
  specific types and facility features for, 344
Compounding accuracy checks, 259–261
  for batch compounding, 309–310
Compounding aseptic containment isolator (CACI), 115, 146–147, 149, 182, 191–192
  enclosure integrity of, 149
  glove practices in, 186
Compounding aseptic isolator (CAI), 116, 147–149, 334, 335
  airflow of, 147
  decontamination/disinfection of, 148
  ergonomics of, 148–149
  material transfer and, 147–148
  recovery time for, 148
Compounding isolators (CIs), 146–149
  garbing for, 156
Compounding pharmacy relationships, 483–484
Compounding Quality Act, 52
Compounding record
  for batch compounding, 310
  documentation and, 460–461
Compounding Sterile Preparations, 328
Comprehensive Accreditation Manual for Hospitals, 36
Computerized provider order entry (CPOE), pediatric compounding and, 105
Construction, 358–359
  contract for, 356–357
Container/closure
  integrity of, 261
  sterilization of, 274
Containers, 58
Containment primary engineering control (C-PEC), 133, 138, 337–338
  venting of, 149–150
Containment secondary engineering control (C-SEC), 181–182, 190–191, 337–338, 342
Containment segregated compounding area (C-SCA), 181, 182, 342–343
  cleanliness zone of, 429
Contamination, 4
  of doses, 2
Continuing education
  analysis of, 319–320
  application of, 319, 320
  comprehension of, 319, 320
  CSP topics and, 319
  evaluation of, 320
  knowledge and, 319, 320
  resources for, 320
  synthesis of, 320
Control number, 231
Controlled air environment, 433
Controlled areas, transport into, 287
Controlled Environment Magazine Buyer's Guide, 121
Controlled Environment Testing Association, 28
Controlled environmental quality program elements, 430
Controlled room temperature, 220, 284–285
Controlled substances, handling, 293

Controlled Substances Act, 293
Corrective action levels, 464
Counter disinfecting, 419
Coveralls, 159
Coyne, Joseph W., 171–202
Critical access hospitals pharmacies, 10
Culture media, 273
  biological issues with, 268
  fill of, 273
  method suitability and, 273
  preparations, 221
Current good manufacturing practices (cGMP), 162
Custom reconstitution diluents/process, ACS and, 383
Cyclophosphamide, 174, 194
Cysteine (L-cysteine), 96–97
Cytokines, 114

D

Dactinomycin, 216
Data analysis, quality assurance, 464, 467
Data collection, quality assurance, 464
Deactivation agents, 126–127, 412
Decontamination, 412, 413
  agents for, 126–127
  EPA-approved agents for, 117
Degradation type cleaning solutions, 194
DEHP toxicity, 101
Delivery
  methods of, 295–296
  pneumatic tube systems and, 296
Department of Transportation (DOT) hazardous waste transport, 196
Depyrogenation, 254–255, 274–275
Det Norske Veritas (DNV-GL Healthcare), 9, 12, 480
Dextrose injection 5%, 55
Diazepam, 216
Diethylhexyl phthalate (DEHP), 90, 101
Difficult to compound, 51
Direct compounding area, 134–135, 163
Discontinued orders, 406, 407
Disinfectants, 126, 414
  activity levels of, 416
  adverse effects of, 418
  for buffer, ante areas, 417, 418
  choice of, 415–416
  pollution prevention and, 417, 418
  primary engineering controls and, 416–417
  regulation of, 414–415
  resistance to germicidal chemicals and, 415
  safe storage, mixing of, 419–420
Disinfection, 409–423
  ACS and, 399
  assessment form for, 411
  biological issues in, 278–280
  buffer area, ante area, 469–472
  competency evaluation for, 448–449
  of facility, 359–360
  frequency, compounding areas, 413
  hazardous drugs and, 412, 413
  program setup for, 420–421
  rotation and, 419
  supplies for, 126
Dispensing, documentation, 246
D-listed drugs, 194–195, 292
Dobutamine, 239
Documentation, 243–248
  of air sampling, 434
  batch compounding record and, 310
  of compounded sterile preparation, 245–246
  compounding record and, 460–461
  of environmental monitoring, 246–247
  of finished preparation, 258
  legal situations and, 244
  master formulation records and, 457
  medication-related records and, 244
  other records and, 461
  outside organizations and, 243
  personnel and, 247
  of quality assurance, 247
  of quality improvement, 244
  retention of, 248
  for special drug categories, 244–245
  workload justification and, 244
Dopamine, 239
Dose reconciliation to determine waste, 407
Downtime
  of ACS, 400–401
  plan, recovery for, 402
Doxorubicin, 184
Drug delivery, stability related to, 218–219
Drug Enforcement Administration (DEA), 293, 481
  documentation and, 243
Drug incompatibilities, 42, 44
Drug Quality and Security Act, 5, 7–8, 51–52, 475
  compounding and, 16
  standards of, 14–16
Drug waste, nonhazardous, 292–293
Dry-heat sterilization, 254–255

E

Efficiency, 370–371
Electronic medication order, 258
Elimination type cleaning solutions, 194
Emergency management plan, 348
Emergency power, 125
Employee
  safety for, 369–370
  satisfaction of, 370
  training, orientation of, 318–319
Emulsified oils, 56
Emulsifiers, 57–58
Endotoxin testing, 262–263
Enoxaparin, 81–82
Environmental monitoring, 123–124, 246–247
  automated compounding system and, 397–398
  frequency of, 433–434
  hazardous drug contamination and, 434–435
  program for, 426
Environmental Protection Agency, 28, 194–195
  approved disinfectants and, 117
  hazardous waste transport and, 196
  labeling and, 414
Environmental quality and control, 425–436
Environmental sampling program, 275, 341–342, 360, 430
Environmental temperatures, clinical setting and, 219–220
Epinephrine, 194–195, 237
Equipment
  ancillary, 121–131
  placement of, 341
Erickson, Bruce A., 363–407
Ethyl alcohol, 55
  cleansing products, 156–157
Ethylene oxide gas sterilization, 255
Etoposide, 195
Exactamix (Baxter Healthcare Corporation) ACD, 76
Excipients, 87, 88
Existing facility, 348–349
Expiration date, 213
Expired sterile commercial products, 293
Extended Stability for Parenteral Drugs, 223

F

Face masks, 127
Facility maintenance
  cleaning and disinfection of, 359–360
  environmental sampling, testing of, 360
  recertification and, 360
Facility planning, 346
  architectural schematic plan for, 355–356
  commissioning for occupancy, 359
  construction of, 358–359
  construction contract and, 356–358
  design of, 116
  existing facility and, 348–349
  functional program for, 351–355
  ISO Class 5 cleanrooms and, 350–351
  need identification and, 347
  need justification and, 347–348
  robots and, 349–350
  specific compounding types and, 344
  strategic master plan for, 346–348
Fatigue mats, 126
Filgrastim, 216
Filter(s)
  cautions for, 252
  integrity of, 251–252
  integrity testing for, 272
  selection of, 250–251
  sterilizing-grade, 271
Filtrate volume, 251
Filtration, sterilization by, 250–251
Final preparations, batch compounding testing, quarantine, 309–310
Fingertip testing kits/media, 129
Finished preparation
  bacterial endotoxin testing and, 262–263
  components in, 258–259
  compounding accuracy checks for, 259–260
  documentation practices for, 258
  medication order for, 257–258
  pH testing and, 263
  physical inspection of, 261
  potency, stability testing and, 263
  release checks, tests for, 257–265
  sterility testing and, 261–262
First air, 134
  503B pharmacies. *See* Outsourcing facilities
Fixed oils, 56
Floor disinfecting, 418–419
Fluid thioglycollate medium, 262
Food and Drug Administration (FDA)
  on aluminum contamination, 97, 100
  biological agents regulation of, 113
  on difficult to compound designation, 51
  on documentation, 243
Food and Drug Administration Modernization Act (1997), 14
Food, Drug, and Cosmetic Act (FDCA), 4,16, 18, 161–162, 475
  documentation and, 243
  drug products exempt from compounding, 51
Forced air sterilizer, 254
Form 483 issues and, 477
  NECC investigation by, 3–4
  on outsourcing facility, 5, 8, 52, 475–478
  pharmacist oversight and, 2
  on registered outsourcing facility, 16
  Safe Use Initiative, 106
  standalone compounding pharmacies and, 14
  standards enforcement by, 16
Formulation issues, 51–66
Forrey, Ryan A., 121–131, 243–248, 283–294, 409–423
Freezer(s), 124–125, 220

G

Gap analysis, 464
Garbing
  allergen extracts and, 156
  ante-area, 155
  competency evaluation, 447
  compounding isolators and, 156
  high-risk weighing, measuring and, 156
Garment(s), 159
  fit, integrity of, 159–160
Gas producers, ACS and, 382–383
Gene therapy, 114
General duty clause, 25
General pharmacy area, cleanliness zone, 429
Gentamicin master formula sheet, 305–307
Getting Started in Aseptic Compounding, 162, 328
Glass containers, 58
Glass-aluminum contamination, 90–91
Glassware sterilization, 274
Gloved fingertip sampling evaluation, 447–448
Gloves, 128, 157–159
  competency evaluation for, 447
  for hazardous drugs, 184–186
  latex vs nonlatex, 158–159
  powdered vs nonpowdered, 158
  protective, 159
Glycerin, 56
Goggles, 127
Good manufacturing practices, 4, 14, 16
Gowns, 127–128, 159
  for hazardous drugs, 186–188
Gracimetric checks, 260
Gravity compounding, parenteral nutrition, 73, 75
Growth media, 128, 432
Gura, Kathleen M., 81–111

H

Hair coverings, hazardous drugs, 188
Hamberg, Margaret, 478
Hand hygiene, 276–278
  in ante-area, 155–156
  aseptic technique for, 164
  immediate-use compounding and, 40–41
Handbook on Injectable Drugs, 223
Handling procedures, 283–294
Hardware failure, ACS, 401
Hardware-software performance, ACS, 398
Hazardous Drug Working Group, 172
Hazardous drugs, 171–202
  aseptic technique for, 192
  biohazard symbol and, 178
  BSC Class II and, 191
  CACI and, 191–192
  cleaning and, 412, 413, 194
  compounding area designs and, 354
  containment of, 181–182, 194–196
  C-PEC working, 190–191
  deactivating, 193–194
  decontaminating, 193–194
  defining, 175–176, 177
  disposal of, 194–196
  donning PPE, 188–189
  early interventions for, 172
  environment and, 181
  environmental monitoring for, 434–435
  exposure and adverse events, 171–172, 173–175
  gloves and, 184–186
  gowns and, 186–188
  hair coverings and, 188
  handling competency evaluation, 449–450
  labeling, 178–179
  personal protective equipment and, 183–185, 188–189
  PPE disposal and, 189
  practice standards, best practices for, 177–178
  receiving, 179, 337
  reconstituting in vials, 192
  secondary engineering controls and, 337–338
  shoe coverings and, 188
  standards for, 23–26
  state OSHA programs and, 175
  storage of, 180, 285, 337
  supplemental engineering controls for, 182–183
  surface contamination/sampling, 129, 173–174
  training, competence and, 193
  transferring to IV bag, 192
  transport of, 180–181
  USP Chapter 800 and, 175
  withdrawing from ampule, 192–193
  work practices for, 189–192
Hazardous waste
  disposal of, 292
  handling of, 291–292
Health and Human Services, U.S. Department of, 3
  Advisory Committee on Compounding, 16
  standalone compounding pharmacies and, 16
Health Insurance Portability and Accountability Act (HIPAA), 481
Health status, 153–154
Healthcare Facilities Accreditation Program (HFAP), 9
  Pharmacy Services/Medication Use—Acute Care Manual (2016), 13–14
  standards, 10, 12
Heating, ventilation, and air conditioning (HVAC) systems, 340
Heavy metals, 61
HEPA filter(s), 163
  air supply and, 116
  primary engineering controls and, 135
Hetey, Stephen K., 437–443
Hexachlorophene, 90
Hexylresorcinol 0.5%, 56
Higher concentration delivery systems, 218
High-risk compounding, 51
Hinkle, George H., 203–211
Home care setting
  CSP delivery in, 296–297
  pharmacies for, 10
  recycling methods for, 300
  storage in, 298
  waste disposal methods for, 300–301
Hospital Accreditation Manual (2016), 10
Hospital campus, 295–296
  pharmacy in, 10
  recycling methods in, 300
Hospital Pharmacies Status as Drug Manufacturer, 52
Hospital-acquired infections, 409
Human Drug Compounding Outsourcing Facilities, 4
Human particle generation, 153, 154
Humidity controls, 124
  in compounding area, 397
  SEC and, 345–346
Hydrolysis, 217–218

I

Immediate use
  defined, 35–36
  provision, 339
Immediate-use compounding, 21–23, 35–49, 204
  hand hygiene and, 40–41
  injection, infusion preparation for, 39
  labeling of, 231
  materials assembly for, 39–40
  preparation surface cleaning for, 40
  product selection, preparation of, 41
  risks associated with, 37–39
  safe preparation of, 39
Immune globulins, 222
Immunomodulators, 114–115
Immunotherapy, 113
Incompatible medications, 42, 44
Incubation period, 433–434
Incubators, 124
Individual dose lots, 2
Infection control, pediatric compounding, 90
Information system, 483
Infrastructure failure, ACS, 401–402
Infusion(s)
  immediate-use compounding and, 39
  preparation for administration of, 44
Infusion Nurses Society, 40–41
Infusion pharmacy, 17
Injection(s)
  drug solution into IV container, 168
  immediate-use compounding, 39
  pediatric pain minimization of, 87
  safety and, 41–43
In-process testing, 309
Instability, 214
Institute for Environmental Sciences and Technology, 28
Institute for Safe Medication Practices (ISMP), 28
  best practice and, 29
  cartridge prefilled syringes survey of, 38
  dilution practices survey of, 38
  Safe Practice Guidelines for Adult IV Push Medications, 38
  safety initiative of, 106
Institutional setting
  storage in, 298
  waste disposal methods in, 300
Insulin, 216
International Journal of Pharmaceutical Compounding, 62
International Organization for Standardization (ISO), 28–29
  ISO Class 5 environment, 36, 42, 69, 116, 133, 276, 350–351
  ISO Class 7 environment, 36, 116, 276, 342, 343
  ISO Class 8 environment, 116
  particulate matter in room classification and, 334
  standards for cleanrooms, associated environments, 30
Intradermal injections, pediatric, 86
Intramuscular injections, pediatric, 83, 84–85
Intraosseous injections, pediatric, 86
Intrathecal injections, pediatric, 86–87
Intravenous admixture, 36
Intravenous delivery, pediatric, 82–83
Inventory control, sterile commercial drugs, 286
Iodophors, 157
Iso-osmotic, 60
Isopropyl alcohol (70%), 42
Isopropyl alcohol cleansing products, 156–157
Isotonic, 60
IV admixtures
  compounding of, 1–2
  nurses preparation of, 1–2

J

Job descriptions, 454
Joint Commission, The (TJC), 9, 480–481
  accredited healthcare sites and, 10

documentation and, 243
hospital sterile preparation facilities and, 339
Medication Compounding Certification Program, 17–18, 36
medication errors and, 38–39
medication labeling of, 44
Medication Management Standard, 35
standards of, 10
sterile compounding locations accredited by, 10
urgent situations and, 36
USP Chapter 797 and, 11–12
vials and infection prevention and, 42
Joint Council of Allergy, Asthma, and Immunology, 46
Joint Task Force, allergen immunotherapy, 46

K

Kienle, Patricia C., 425–436, 453–472
Klang, Mark G., 51–66
Kuban, Patricia J., 227–242

L

Labeling, 227–242, 461
of active ingredients, 229
auxiliary, 232, 236, 239
barcodes and, 240
of batch, 231–232
of beyond use date, 229
color, graphics and, 239
of finished preparation, 261
general guidelines for, 228–232
for home care settings, 237–238
immediate-use, 231
for institutional settings, 232–235
optional, 236, 239
other considerations for, 235
of parenteral nutrition, 72
patient-specific, in-house, 233–234
for perioperative, procedural area settings, 236–237
routes of administration and, 229–230, 232
safe use information and, 230
shipping outside facility and, 234–235
single-dose or bulk package designation and, 230
specialty, 240
storage conditions and, 230, 232
tall man letters and, 239–240
total amount/volume of preparation and, 229, 232
USP requirements for, 228–230
Lactated Ringer's injection, 55
Laminar airflow hood(s), 42, 162–163
Laminar airflow system, 116
Laminar airflow workbench(es), 116, 136–138
blower above work surface and, 136–137
blower below work surface and, 137
vertical air flow and, 137, 138
Latex allergies, 437–443
allergens source and, 438
best practices and, 441
contact avoidance and, 439–440
diagnosis of, 439
future developments, therapies for, 442
management of, 441
types of reactions in, 438–439
Leaching, 251
Lean Six Sigma downtime, 371–372
Learning goals, 320
Lighting level, uniformity, 343, 345
Lipid emulsions
microbial contamination and, 222
repackaging of, 102–103
Liquid polyethylene glycol, 55
Lockers, 125–126
Long-term care pharmacy, 17
recycling methods for, 300
Look-alike/sound-alike medications, 41
Lorazepam, 216
Lot number, 231
Luer-lock syringes, 118

M

Maintenance, ACS, 399–400
Mansur, Jeannell M., 35–49, 480–481
Manual compounding process, 383, 384–385
Manufacturer information, 223
Manufacturing, defined, 8
Masks, 159
Master formula, 307
Master formula sheet, 304, 307, 310
equipment supplies and, 308
example of, 305–307
sample label for, 309
Materials, 483
McElhiney, Linda F., 161–170, 445–451
Mechanical convection sterilizer, 254
Media fill
challenge testing, 447
testing, 273–274
testing kits/media, 129
Medicaid, standards, 9
Medicare
compounded preparations oversight by, 3
standards of, 9
Medication
labeling, 44
order transcription for, 257–258
reconstitution of, 38, 41
selection of, 41
Medication errors, immediate-use compounding, 37–39
MEDMARX, 365–366
MedWatch Safety Alert, syringes and, 476–478
Methyl paraben, 41
Microbial contamination
immediate-use compounding and, 37
risk considerations for, 267–268
risk levels for, 19–21, 334, 335
risk levels exemptions for, 19, 22–23
Microbiological surface testing kits/media, 129
Millwork, 122
Minibags, 2
Mirror to Hospital Pharmacy, 1
Model Curriculum for Pharmacy Technician Training, 324, 326
Model State Pharmacy Practice Act, 8
Modular cleanroom, 353, 355
Monoclonal antibodies (MABs), 114
Mops, mop systems, 127
Multichamber bags, parenteral nutrition, 72–73
Multiple ingredients, ACS and, 383
Multiple-dose containers, 58–59
Multiuse vials, 41–42
contamination control in, 222–223
Multivitamins
pediatric compounding and, 96
pediatric, adult parenteral products of, 98–99

N

National Association of Boards of Pharmacy (NABP)
compounding regulations of, 8–9
outsourcing facilities and, 478–479
record retention and, 310
standalone compounding pharmacies and, 16
National Institute for Occupational Safety and Health (NIOSH), 25
hazardous drug alert by, 26, 27, 172
hazardous drug list of, 115, 176, 177, 278, 291
incubators and, 124
sterile compounding and, 37
National Institute of Standards and Technology (NIST), incubators, 124
National Patient Safety Goal(s), 11–12
medication labeling and, 44, 45
National Sanitation Foundation, 29
Needles
aseptic technique for, 165–166
parts of, 166
Network failure, ACS, 401
New drug application, 52
New England Compounding Center, 3–5, 162, 475
New orders, 406, 407
New York Times, 340
Nitroglycerin, 216
Noise level, 345
Nonaqueous vehicles, 56
Nonhazardous drug waste, 292–293
NRL, 437–438
allergens identification of, 439
closures and, 440–441
risk factors for sensitivity development and, 440
sensitizing antigens in, 440
NSF International, 29–30
Nuclear pharmacy, 204
layout of, 205

O

Occupational Safety and Health Act (1970), 25
Occupational Safety and Health Administration
antineoplastics and, 175
Hazard Communication Standard of, 176, 178
hazardous drugs and, 172
standards of, 25–26
Technical Manual, 175
Office of Inspector General, 9
Off-premises, CSP delivery, 296–297
Ommaya reservoirs, pediatric, 86
Oncology Nursing Society, 172
Open isolators, 147
Ophthalmic formulations, 62, 63
buffers, pH and, 62
sterility of, 63
tonicity of, 62
viscosity of, 62–63
Osteen, Richard B., 153–160, 303–312
Outsourcing, 473–485
national trends and, 473–474
organizational pharmacy responsibilities in, 482–483
of parenteral nutrition, 77
questions for, 483–484
of radiopharmaceuticals compounding, 209
Outsourcing facility(ies)/pharmacy, 52, 339
accrediting organizations and, 479–481
ASHP and, 481–482
DEA and, 481
FDA Form 483 issues and, 477
HIPAA and, 481
hospital preparations and, 474
laws, regulations, standards for, 475–477
state boards of pharmacy and, 478–479
Overwrap removal, 219
Oxidation, 217–218

P

Paclitaxel, 195
Parabens, 56
Parenteral admixtures, preparation of, 2

Parenteral formulas, 62
  modalities of, 58
Parenteral medication
  aluminum in, 95
  benzyl alcohol and, 87–89
  pediatric safety for, 103–104
  propylene glycol and, 88
Parenteral nutrition
  customized, 73
  errors reported for, 69
  in hospital pharmacy practice, 67–68
  labeling of, 72
  multichamber bags for, 72–73
  order review of, 71–72
  outsourcing, 77
  pediatric, 95–101
  prescribing, 70
  quality assurance and, 75–76
  safety aspects of, 69–70
  solubility issues in, 215–216
Parenteral nutrition compounding, 67–79
  accuracy of, 76–77
  ambient light protection and, 100–101
Parenteral preparations
  impurities and, 61
  large volume, 218
  particulates and, 60–61
  pH and, 60
  physiologic norms for, 59
  pyrogenicity and, 60
  stability of, 61
  tonicity of, 60
Partially-used packages, 286
Particle management, 134
Particulate(s), 261
  load, 251
Patient
  monitoring, complaint system for, 462
  safety and, 365–366
  -specific labeling, 233–234
  training , 462
PCMX, 157
Pediatric compounding,
  ADC safety considerations in, 103
  aluminum toxicity and, 90–95
  ambient light protection and, 100–101
  benzyl alcohol and, 88–89
  concentration considerations in, 81–82
  considerations in, 81–111
  delivery routes for, 82–87
  drug delivery challenges of, 81–82
  excipients impact on, 87, 88
  injection pain minimization and, 87
  parenteral nutrition and, 95–101
  propylene glycol and, 88, 89
  repackaging emulsions, syringes for, 102
  rule of 6 for, 104–105
  safety and information support for, 105
  safety initiatives, considerations and105–106
  skin cleaning solutions and, 89–90
  smart pumps and, 105
  standardization issues for, 104
  storage containers for, 90–91, 101
  storage/dispensing considerations for, 104
  volume limits, intramuscular injections by age, 84
Pediatric patient, parenteral medication safety, 103–104
Pediatric Pharmacy Advocacy Group, safety initiative, 106
Personal protective equipment (PPE), 115, 116
  for hazardous drugs, 183–189
Personnel
  cleansing, garbing and, 153–160, 163–164
  microbial testing for, 275
  monitoring, 276
  preparation of, 153–156
  records for, 247
Personnel training, 445–446
  aseptic manipulation competency evaluation and, 448
  cleaning, disinfecting competency evaluation and, 448–449
  competency evaluation and, 445–451
  garbing, gloving competency evaluation and, 447
  gloved fingertip sampling evaluation and, 447–448
  hazardous drug handling competency evaluation and, 449–450
  media fill challenge testing and, 447
  policies and procedures for, 455–456
  written knowledge assessment and, 446–447
Pew Charitable Trusts survey (2015), 8
pH
  buffers for, 57
  ophthalmic formulations and, 62
  parenteral preparations and, 60
  solubility and, 215
  testing for, 263
Pharmaceutical services, 9
Pharmacist education, 315–321
Pharmacy
  adverse events and, 1
  school education for, 316–318
Pharmacy Compounding Accreditation Board, standards, 17
Pharmacy Compounding Advisory Committee, exemptions, 51
Pharmacy Purchasing & Products Suppliers Guide, 121
Pharmacy school education
  current instruction on CSPs in, 317
  curriculum changes in, 317–318
  practitioner perceptions of, 317
  professional perceptions of, 316
  student perceptions of, 316–317
Pharmacy technician, 323–331
  advances in education, training of, 323–324
  certification for, 326, 327
  competency, evaluation of, 326–327, 329
  educational program accreditation of, 325–326
  educational programs for, 325
  educators and, 324–325
  hazardous drug training for, 328–329
  measuring performance of, 329
  orientation for, 327–328
  regulation of, 329–330
  sterile preparations and, 324, 325, 327
Phenol, 56
Phenylmercuric benzoate 0.1%, 56
Phosphate salts, 61
Phosphorus solubility factors, 95–96
Photochemical decomposition, 218
Physical incompatibilities, 214–217
Physostigmine salicylate, 194
Pinnacle (B. Braun Medical, Inc.) ACD, 76
Plastic containers, 59
Plastic toxicity, 90
P-listed drugs, 194–195, 291
Point-of-care activation systems/devices, 42, 219
Point of preparation testing, 261
Policies and procedures
  for beyond-use dating, 461
  compounding personnel responsibility and, 454–455
  documentation and, 457–461
  job descriptions and, 454
  other sources of, 457
  patient/caregiver training in, 462
  patient monitoring, complaint system and, 462
  personnel training/evaluation and, 455–456
  quality assurance and, 461
  standard operating procedures and, 456–457, 458–459, 460
  storage and, 461
  topics covered by, 455
  writing, 453–454
Polyvinyl chloride toxicity, 90, 91
Pore size, 251
Positron emission tomography (PET) drugs, 204
Potassium chloride, 2
Potency testing, finished preparation, 263
Power, Luci A., 171–202
Power interruptions, 348
Precision, ACS, 396–397
Preparation
  name, 231–232
  -specific experimental studies, 223–224
Pressure
  in compounding area, 397–398
  differential monitoring of, 124, 431–432
Preventative maintenance, 399–400
"Prevention of Medication Errors in the Pediatric Inpatient Setting," 105
Primary engineering controls (PECs), 133–151
  air cleanliness and, 135–136
  air sampling and, 429–430
  biological safety cabinets and, 138–146
  certification of, 150
  compounding isolators and, 146–149
  direct compounding area and, 134–135
  disinfectants and, 416–417
  HEPA filters and, 135–136
  laminar airflow workbenches and, 136–138
  performance verification of, 430–431
  placement of, 429
  purchasing and, 150–151
  unidirectional airflow and, 133–134
Principles of Sterile Product Preparation, 3
Probability
  pathway modeling and, 370–371
  of nonsterile unit, 270
Probability pathway modeling, 370–371
Product integrity, 286
Propofol, 56
Proprietary bag, vial systems, 339
Propyl paraben, 41
Propylene glycol, 55
PTAC accreditation, 326
PTCB certification, 326
PTEC organization, 324–325
Purified water, 55
Purity, maintaining, 295–301
Pyrogen tests, 129–130
Pyrogenicity, 60

Q

Quality assurance, 462–464
  for compounded preparations, 461
  indicators for, 465–467
  for parenteral nutrition, 75–76
  records for, 247
Quality control, 462
Quality improvement, documentation, 244
Quaternary ammonium compounds, 157

R

Radionuclide generators, 210
Radiopharmaceuticals, 203–211, 338
  airborne contamination control and, 206–208
  aseptic technique for, 207–208
  aseptic technique evaluation and, 208–210
  expiration of, 210

microbial risk levels for, 203–205
nuclear pharmacy layout and, 205
nuclear pharmacy personnel training and, 208–209
storage, use of radionuclide generator systems and, 210
surface contamination and, 205–206
Ready-to-use products, 219
Recalls, 483
Receiving
documentation for, 245
of hazardous drugs and, 179
of sterile commercial products, 283–284
Recertification
facility and, 360
records for, 247
Record retention, 248
for batch compounding, 310
Recycling methods, 300
Reduction, 217–218
Reece, Kelley, 113–120
Refrigerators, 124–125
wireless monitoring of, 126
Remington: The Science and Practice of Pharmacy, 223
Remodeling facility, 355
Repackaging, pediatric compounding and, 102–103
Repeatability monitoring, ACS, 396–397
Repetitive motion injuries, 369
Request for information, 356
Request for proposal, 356–357
Resource Conservation and Recovery Act, 194–195, 291
Respirators, 127
Returns
of CSPs, 288–289
documentation for, 246
methods for, 299–300
Reverse distributor, 293
Ringer's injection, 55
Risk management, 483
Robotics, 379–380
holding vial body, 379
holding vial neck, 379
space for, 349–350
Room separation, 349
Roux, Ryan, 113–120
Rule of 6, 104–105

S

Safe Handling of Hazardous Drugs, 172
Safe harbor, 14, 15
Safe Injection Practices Coalition, "one and only campaign," 42
Safety data sheet, 176, 178
Sampling plan, 432
Scalp vein catheters, 82
Schneider, Philip J., 1–6, 315–321
Secondary engineering controls (SEC), 333–362
air cleanliness and, 334
allergen extracts and, 338
buffer, ante areas and, 340–341
cleaning, disinfecting and, 342–343
CSP classification and, 336
environmental sampling, testing and, 341–342
equipment, supplies placement and, 341
functional requirements of, 333–334
hazardous drugs and, 337–338
humidity and, 345–346
HVAC systems and, 340
immediate-use provision and, 339
lighting level, uniformity and, 343, 345
low-risk level CSPs and, 334–335, 337
microbial contamination risk levels and, 334, 335
noise level and, 345
performance verification and, 430–431
proprietary bag, vial systems and, 339
radiopharmaceuticals and, 338
segregated compounding area and, 334–335, 337
surface characteristics and, 340–341
Security, refrigerator/freezer, 125
Segregated compounding area, 334–335, 337
cleanliness zone for, 429
Selenium, 195
Self-regulation, 2
Shelving, 125–126
disinfecting, 419
Shoes
covers for, 159
hazardous drugs covers for, 188
Single dose containers, 58–59
Single-use vial, 41, 42
Smart pumps, pediatric compounding and, 105
Social Security Act, 9
Sodium chloride (normal saline), 55
Software failure, ACS, 401
Solubility, 214–215
calcium-phosphate issues in, 215–216
larger organic ions and, 215
parenteral nutrition and, 215–216
pH and, 215
Solubilizers, 57, 58
Solutes, 56
Solution characteristics, 251–252
Sorption, 216, 251
Soybean-casein digest medium, 262
Specialized drug delivery systems, 298–299
Specialty pharmacy, 17
Spill kits, 118–119
Spivey, Susan, 113–120
St. John, Keith H., 267–281
Stability
criteria for, 214
drug delivery and, 218–219
factors affecting, 217
maintaining for CSPs, 295–301
microbiology tests and, 268–269
parenteral preparations and, 61
published information on, 223
testing of finished preparation, 263
Standalone compounding pharmacies, 14. *See also* Outsourcing facilities
Standardize 4 Safety, 106
Standardized medication administration times, 406, 407
Standards of practice, 3, 7–33, 456–457, 458–459, 460
State boards of pharmacy, 3
compounding regulations of, 7–8
outsourcing pharmacies and, 478–479
policy inconsistencies and, 8–9
standalone compounding pharmacies and, 16
USP Chapter <797> and, 7
Static-air sterilizer, 254
Steam sterilization, 252–254
Sterile commercial drugs/products
inventory control of, 286–287
receiving, 283–284
Sterile compounding, 36
area floor plan for, 432
workflow systems, 364–365, 370, 395
Sterile preparation formulation, 51–66
Sterile water, 55
Sterility, 367–369
assurance of, 249–256, 270
biological issues in, 269
CSPs from nonsterile ingredients and, 249–250
CSPs from sterile ingredients and, 249
finished preparation testing for, 261–262
limitations of, 220–221
maintaining, 295–301
ophthalmic formulations and, 63
testing for, 129–130, 272–273
Sterilization, 53
biological issues in, 269
of glassware, container closures, 274
validation of, 270
Sterilization methods
dry heat, 254–255
filtration, 250–252, 270–272
gas, 255
steam, 252–254
Sterilizing-grade filter, 271
Storage, 213–226
conditions, 284–285
of CSPs, 288–289
documentation for, 245
of hazardous drugs, 180, 285
in home care setting, 298
in institutional setting, 298
monitoring conditions in, 285–286
policies and procedures for, 461
specialized drug delivery systems and, 298–299
Street clothes, accessories, 155
Stuhan, Mary Ann, 323–331
Subcutaneous injections, pediatric, 83–84, 85
Sufentanil, 216
Supplies, 126–130, 287
ancillary, 121–131
placement of, 341
Supply carts, 122
Surface(s)
automated compounding system sampling and, 398
immediate-use compounding and, 40
monitoring of, 275–276
secondary engineering controls and, 340–341
Surface contamination
by hazardous drugs, 173–174
by radiopharmaceuticals, 205–2061
Suspensions, automated compounding systems and, 382
Sutton, Scott, 478
Syringes(s), 59
aseptic technique for, 164–165
ISMP alert about, 476
marking, 165
parts of, 164, 165
photographic documentation for, 260
pull-back accuracy check for, 259–260
racks for, 378
repackaging, 102–103
visual checks of, 260

T

Tacky mats, 130
Tallman lettering, 41, 239–240
Technology, 363–407
automated compounding systems and, 374–383
evolution of, 364–365
implementation of, 391–395
manual processes assessment and, 383–386
project planning for, 387–390
reasons for, 365–372
solutions assessment for, 386–387
sterile compounding workflow systems and, 372–374, 375
workflow software and, 381–383
Temperature control, 124, 286

in compounding area, 397
monitoring, 220
packaging systems and, 297
Terminal sterilization, 53, 270
Thiopeta, 185
Tirumalai, Radhakrishna, 267–281
Tonicity
agents, 57
of ophthalmic formulations, 62
of parenteral preparations, 60
Total nutrient admixture (TNA), 67
emulsion integrity and, 216
microbial contamination and, 222
pediatric, 95–96
Total parenteral nutrition (TPN), 56
contamination and, 221–222
Total particle counts, 431
Trace elements, 97
Training
biological issues in, 280
records for, 247
Transfer carts, 122
Transport
containers for, 297–298
into controlled areas, 287
of hazardous drugs, 180–181

U

U-listed drugs, 194–195, 292
Umbilical catheters, 83
Unidirectional airflow, 134
United States Pharmacopoeia (USP), 3
general chapters standards of, 24–25
Sterile Compounding Committee of, 18
USP Chapter <788>, particulates and, 61
USP Chapter <795>, 18
bulk ingredients and, 52
USP Chapter <797>, 3, 5
action levels for microbial contamination and, 464
allergen immunotherapy and, 46, 47
as best practice resource, 35–36
BSL-1, BSL-2 facilities and, 116
bulk compounded medications and, 52
carts and, 122
cleaning, disinfecting and, 410, 412
compounding personnel responsibility and, 19
disinfectants and, 414
garbing standards and, 154
hazardous drugs and, 172–173
high-risk compounding and, 51
Joint Commission standards and, 11–12
microbial contamination and, 19–23
nonsterile active ingredients and, 53
parenteral nutrition and, 76–77
shelving and, 125
standard operating procedures and, 458–459
state boards of pharmacy and, 7–8
USP Chapter <800>, 175, 176
BSL-2 facilities and, 116
cleaning, disinfecting and, 412
C-PEC requirements and, 138
deactivation agents and, 126
standard operating procedures and, 459
standards and, 23–24
USP-National Formulary, 10, 52, 53
standards, 18
Utility interruptions, 348

V

Vaccines, 113–114
Valrubicin, 195
Vehicles, 55
Vial(s)
aseptic technique for, 166–167
piercing with needle, 167
racks for, 377
Visual incompatibilities, 214
Visual inspection
of automated compounding systems, 383
of batch compounding final preparations, 309
Vitamin A, 216
Volumes, very small/large, 383
Volumetric air samplers, 123
Voriconazole, 229

W

Warfarin, 195–196
Waste
compounding materials and, 289–291
disposal methods for, 300
documentation and, 246
handling hazardous, 291
management of, 289–291
reduction of, 370–72
Water-miscible solvents, 55–56
Websites, 547–568
Wipers, 127
Workflow management, 364–365
Workload
assessment of, 384, 386
data collection examples for, 406
data collection questions for, 405
Written procedures, 54–55

Y

Yaniv, Angela W., 249–256, 257–265
Yardley, William, 340
Y-site administration, 218–219